BEHOLD-1 and -2: phase 1/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers

Stephanie Lheureux, Diane Provencher, Sofia Baka, Ruben Kowalyszyn, Tim Schutte, Yüksel Ürün, Xing Zeng, Ana Oaknin, Domenica Lorusso, Isabelle Ray-Coquard, Victor Moreno, Katriina Jalkanen, Lisa Liu Burström, Marloes G.J. van Dongen, Valentina Boni, Jung-Yun Lee, Philippe L. Bedard, Izabela A. Malinowska, Morrys Kaisermann, William McKean

Open source

DOI: 10.1016/j.ijgc.2026.105607
Published: 2026-09
Container: International Journal of Gynecological Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ijgc.2026.105607,
  title = {BEHOLD-1 and -2: phase 1/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers},
  author = {Stephanie Lheureux and Diane Provencher and Sofia Baka and Ruben Kowalyszyn and Tim Schutte and Yüksel Ürün and Xing Zeng and Ana Oaknin and Domenica Lorusso and Isabelle Ray-Coquard and Victor Moreno and Katriina Jalkanen and Lisa Liu Burström and Marloes G.J. van Dongen and Valentina Boni and Jung-Yun Lee and Philippe L. Bedard and Izabela A. Malinowska and Morrys Kaisermann and William McKean},
  year = {2026},
  journal = {International Journal of Gynecological Cancer},
  doi = {10.1016/j.ijgc.2026.105607},
  url = {https://doi.org/10.1016/j.ijgc.2026.105607}
}

RIS

TY  - JOUR
TI  - BEHOLD-1 and -2: phase 1/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers
AU  - Stephanie Lheureux
AU  - Diane Provencher
AU  - Sofia Baka
AU  - Ruben Kowalyszyn
AU  - Tim Schutte
AU  - Yüksel Ürün
AU  - Xing Zeng
AU  - Ana Oaknin
AU  - Domenica Lorusso
AU  - Isabelle Ray-Coquard
AU  - Victor Moreno
AU  - Katriina Jalkanen
AU  - Lisa Liu Burström
AU  - Marloes G.J. van Dongen
AU  - Valentina Boni
AU  - Jung-Yun Lee
AU  - Philippe L. Bedard
AU  - Izabela A. Malinowska
AU  - Morrys Kaisermann
AU  - William McKean
PY  - 2026
JO  - International Journal of Gynecological Cancer
DO  - 10.1016/j.ijgc.2026.105607
UR  - https://doi.org/10.1016/j.ijgc.2026.105607
ER  -

APA

Lheureux, S., Provencher, D., Baka, S., Kowalyszyn, R., Schutte, T., Ürün, Y., Zeng, X., Oaknin, A., Lorusso, D., Ray-Coquard, I., Moreno, V., Jalkanen, K., Burström, L. L., Dongen, M. G. V., Boni, V., Lee, J., Bedard, P. L., Malinowska, I. A., Kaisermann, M., & McKean, W. (2026). BEHOLD-1 and -2: phase 1/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers. International Journal of Gynecological Cancer. https://doi.org/10.1016/j.ijgc.2026.105607

Source records

crossref · retrieved 2026-11-10T12:41:47.452Z